Intercept could net $62.9m at middle of IPO price range
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals set preliminary pricing on 27 September for its initial public offering at $13 to $15 per share, which will give the New York-based company $62.9 million in net proceeds if all 4.3 million shares of common stock plus 645,000 additional shares are sold at the mid-point of the initial price range.